BNP Paribas Financial Markets’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$47.3M Sell
860,500
-96,526
-10% -$3.95M 0.02% 796
2026
Q1
$31.8M Buy
957,026
+273,373
+40% +$8.15M 0.02% 900
2025
Q4
$20.4M Buy
683,653
+612,189
+857% +$20M 0.01% 1168
2025
Q3
$2.58M Sell
71,464
-7,516
-10% -$248K ﹤0.01% 2440
2025
Q2
$2.84M Sell
78,980
-472,049
-86% -$17.6M ﹤0.01% 2234
2025
Q1
$21.7M Buy
551,029
+491,319
+823% +$16.5M 0.01% 996
2024
Q4
$1.8M Sell
59,710
-58,275
-49% -$1.67M ﹤0.01% 2428
2024
Q3
$2.76M Sell
117,985
-24,661
-17% -$539K ﹤0.01% 1867
2024
Q2
$2.54M Buy
142,646
+56,045
+65% +$894K ﹤0.01% 1777
2024
Q1
$1.32M Sell
86,601
-207,006
-71% -$3.3M ﹤0.01% 2323
2023
Q4
$5.01M Sell
293,607
-874,176
-75% -$10.2M 0.01% 1403
2023
Q3
$9.76M Buy
1,167,783
+598,994
+105% +$8.35M 0.01% 906
2023
Q2
$14.1M Buy
568,789
+209,537
+58% +$5.41M 0.02% 771
2023
Q1
$5.4M Buy
359,252
+167,841
+88% +$2.55M 0.01% 1206
2022
Q4
$2.26M Sell
191,411
-135,512
-41% -$984K ﹤0.01% 1694
2022
Q3
$1.94M Buy
326,923
+169,010
+107% +$1.11M ﹤0.01% 1984
2022
Q2
$671K Buy
157,913
+49,051
+45% +$306K ﹤0.01% 2483
2022
Q1
$1.04M Sell
108,862
-671
-0.6% -$7.77K ﹤0.01% 2295
2021
Q4
$2.08M Buy
109,533
+86,718
+380% +$2.25M ﹤0.01% 1991
2021
Q3
$759K Buy
22,815
+18,199
+394% +$563K ﹤0.01% 2531
2021
Q2
$179K Sell
4,616
-14,494
-76% -$569K ﹤0.01% 2892
2021
Q1
$921K Sell
19,110
-81,498
-81% -$3.92M ﹤0.01% 2184
2020
Q4
$5.23M Buy
100,608
+74,504
+285% +$2.52M 0.01% 1106
2020
Q3
$699K Buy
26,104
+14,077
+117% +$324K ﹤0.01% 2005
2020
Q2
$234K Sell
12,027
-30,850
-72% -$497K ﹤0.01% 2431
2020
Q1
$422K Buy
42,877
+32,782
+325% +$414K ﹤0.01% 2439
2019
Q4
$112K Sell
10,095
-1,976
-16% -$15K ﹤0.01% 3243
2019
Q3
$67.8K Buy
12,071
+5,099
+73% +$35.5K ﹤0.01% 3328
2019
Q2
$60.3K Sell
6,972
-6,145
-47% -$46.5K ﹤0.01% 3304
2019
Q1
$105K Buy
13,117
+9,255
+240% +$50K ﹤0.01% 3092
2018
Q4
$15.8K Sell
3,862
-6,920
-64% -$34.4K ﹤0.01% 3185
2018
Q3
$60.4K Sell
10,782
-404
-4% -$4.62K ﹤0.01% 2971
2018
Q2
$147K Buy
11,186
+422
+4% +$5.8K ﹤0.01% 2594
2018
Q1
$153K Sell
10,764
-745
-6% -$9.52K ﹤0.01% 2959
2017
Q4
$94.4K Buy
11,509
+6,449
+127% +$56.3K ﹤0.01% 3335
2017
Q3
$60K Sell
5,060
-321
-6% -$3.66K ﹤0.01% 3052
2017
Q2
$54.1K Buy
5,381
+5,066
+1,608% +$56.7K ﹤0.01% 3149
2017
Q1
$3.67K Sell
315
-1,781
-85% -$12.8K ﹤0.01% 3380
2016
Q4
$9.75K Sell
2,096
-631
-23% -$3.7K ﹤0.01% 3469
2016
Q3
$21.1K Buy
2,727
+1,292
+90% +$8.31K ﹤0.01% 2863
2016
Q2
$8.7K Buy
+1,435
New +$11.7K ﹤0.01% 2974
2016
Q1
Sell
-3,700
Closed -$44.1K 3046
2015
Q4
$44.1K Sell
3,700
-3,855
-51% -$48.7K ﹤0.01% 2391
2015
Q3
$76.2K Buy
7,555
+4,614
+157% +$68.7K ﹤0.01% 2564
2015
Q2
$48.8K Buy
2,941
+2,295
+355% +$36.3K ﹤0.01% 2508
2015
Q1
$10K Buy
+646
New +$9.78K ﹤0.01% 2746
2014
Q4
Sell
-1,718
Closed -$18.3K 3071
2014
Q3
$18.3K Buy
1,718
+1,042
+154% +$9.66K ﹤0.01% 3229
2014
Q2
$6.35K Buy
676
+78
+13% +$499 ﹤0.01% 2478
2014
Q1
$3.19K Sell
598
-166
-22% -$983 ﹤0.01% 2528
2013
Q4
$2.98K Buy
+764
New +$3.09K ﹤0.01% 3429

Other funds holding TGTX

BNP Paribas Financial Markets's TGTX Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its TG Therapeutics (TGTX) stake by 10% in Q2 2026, selling an estimated $3.95M and leaving 860,500 shares worth $47.3M. The position accounts for 0.02% of the portfolio, ranked #796.

BNP Paribas Financial Markets first reported a position in TGTX in Q4 2013 and has held it in 49 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • BNP Paribas Financial Markets held 860,500 shares of TG Therapeutics worth $47.3M as of Q2 2026.
  • BNP Paribas Financial Markets sold 96,526 TG Therapeutics shares in Q2 2026, an estimated $3.95M.
  • TG Therapeutics made up 0.02% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #796 holding.
  • BNP Paribas Financial Markets first reported a position in TG Therapeutics in Q4 2013 and has held it in 49 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.